A company that has been researching the active properties of the Nerium oleander plant has joined forces with Jeff Olson to launch an anti-aging line.
Nerium International, a subsidiary of Nerium Biotechnology, has launched the Nerium SkinCare line through an exclusive licensing partnership that culminates in five years of research into the active properties of the Nerium oleander plant.
According to the two companies, the partnership aims to build a global brand through the development and distribution of a range of ‘breakthrough’ products targeting the fast growing anti-aging market.
Nerium Biotechnology was initially founded to fund research into new technology and applications of the plant, and the company hasa service contract with the University of Texas San Antonio.
The medicinal properties of Nerium have been identified as far back as 1,500 years ago, but the research work is the first known study to comprehensively catalogue its properties using scientific experiments and data.
The Nerium Oleander is an ever-green shrub or small trees that can be traced back to Morocco and the Mediterranean region, although it is now grown worldwide, include many warmer regions in the US.
The extract produced from the plant has been clinically tested to treat a series of skin conditions, including age spots, sunburn, acne and cold sores.
Over the course of the five years, various tests that the scientists carried out led them to realize the plant possessed unique properties that demonstrated ‘age-defying’ results in clinical tests, resulting in the Nerium AD skin care line.
According to the company, third party clinical trials have shown that the NeriumAD Age-Defying Treatment ‘dramatically reduces the appearance of fine lines and wrinkles, hyperpigmentation, uneven skin texture, enlarged pores, and aging or sun-damaged skin’.
The product is marketed as a night cream intended for daily use.
“When we realized the potential of our skin care applications, we started looking for the most effective distribution channel available,” said Dennis Knocke, chairman and CEO of Nerium Biotechnology.
The company has chosen to market the product line through direct sales channels and has partnered with Jeff Olson, founder and CEO of Nerium International, to promote and market the line through an exclusive partnership.
The long-term plan is to extend the product line through continued product development and to take the launch beyond the US and North America markets and make it a global product